Morgan Stanley Maintained an Overweight Rating on AbbVie (ABBV)

AbbVie Inc. (NYSE:ABBV) is one of the best high growth stocks. On June 30, Morgan Stanley maintained an Overweight rating and a $250 price target on AbbVie, in light of the company’s recent acquisition announcement.

Recently, AbbVie announced its intention to acquire Capstan Therapeutics, a clinical-stage biotechnology firm specializing in in-vivo cell engineering through RNA delivery platforms, for up to $2.1 billion in cash, contingent upon standard closing conditions. The company has a robust financial foundation, including a 71% gross profit margin and 5.45% year-over-year revenue growth, making AbbVie strategically positioned to integrate this acquisition and advance its innovation pipeline.

A pharmacist handing out a pharmaceutical drug to a patient in a drug store or chemist.

As part of the agreement, AbbVie Inc. (NYSE:ABBV) will gain access to CPTX2309, an in-vivo anti-CD19 CAR-T candidate currently undergoing Phase 1 clinical evaluation for B cell-mediated autoimmune disorders. The acquisition also includes Capstan’s proprietary lipid nanoparticle (LNP) platform, which enables targeted RNA delivery for the in-vivo engineering of specific cell populations.

According to Morgan Stanley, the deal represents a constructive step forward for AbbVie, enhancing its technological capabilities and reinforcing its pipeline in early-stage immunological research.

This move complements AbbVie’s previously outlined growth agenda, which forecasts expansion through 2032, with recent technology acquisitions offering critical optionality and pipeline diversification.

AbbVie Inc. (NYSE:ABBV) is a global biopharmaceutical company focused on the discovery, development, and commercialization of therapies including immunology, oncology, neuroscience, virology, and ophthalmology.

READ NEXT: Dow 20 Stocks List: Ranked By Hedge Fund Bullishness Index and 10 Unstoppable Dividend Stocks to Buy Now.

Disclosure. None.